Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

P623 Therapeutic preferences and outcomes in newly diagnosed patient with inflammatory bowel diseases in the biological era in Hungary. A nationwide study based on the National Health Insurance Fund database

(2017) L. Gonczi et al.   Journal of Crohns & Colitis

Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®

(2016) Joseph C. Marini et al.   AAPS Journal

Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays

(2016) J. Afonso et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review

(2016) Massimo Radin et al.   BIODRUGS

Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence

(2016) Ira Jacobs et al.   BIODRUGS

CT-P13 (Inflectra™, Remsima™) monitoring in patients with inflammatory bowel disease

(2016) Kornelius Schulze et al.   BIOLOGICALS

Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease

(2016) Karin Malíčková et al.   BIOLOGICALS

Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits

(2016) Ellen M.H. Schmitz et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

(2016) Bella Ungar et al.   Clinical Gastroenterology and Hepatology

Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis

(2016) Johannan F. Brandse et al.   Clinical Gastroenterology and Hepatology

Clinical Decision Support Tools: The Evolution of a Revolution

(2016) DR Mould et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease

(2016) Cristina Guiotto et al.   DIGESTIVE AND LIVER DISEASE

A Systematic Review on Infliximab and Adalimumab Drug Monitoring

(2016) Filipa Silva-Ferreira et al.   INFLAMMATORY BOWEL DISEASES

Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples

(2016) Ann Gils et al.   INFLAMMATORY BOWEL DISEASES

Biosimilars in IBD: from theory to practice

(2016) Silvio Danese et al.   Nature Reviews Gastroenterology & Hepatology

Comparison of infliximab drug measurement across three commercially available ELISA kits

(2016) Monique Wei Meng Lee et al.   PATHOLOGY

Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease

(2016) A. S. Strik et al.   Expert Review of Clinical Pharmacology

Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays

(2016) Joana Afonso et al.   Therapeutic Advances in Gastroenterology

Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases

(2015) K. Papamichael et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab

(2015) Henit Yanai et al.   Clinical Gastroenterology and Hepatology

Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting

(2015) Andrea Warman et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies

(2015) Diane R. Mould et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

(2015) Krisztina B. Gecse et al.   Journal of Crohns & Colitis

Significance of low level infliximab in the absence of anti-infliximab antibodies

(2015) Bella Ungar   WORLD JOURNAL OF GASTROENTEROLOGY

Optimizing biological therapy in Crohn’s disease

(2015) Krisztina Barbara Gecse et al.   Expert Review of Gastroenterology & Hepatology

A Review of CT-P13: An Infliximab Biosimilar

(2014) Kate McKeage   BIODRUGS

Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis

(2014) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

Physicochemical characterization of Remsima®

(2014) Soon Kwan Jung et al.   mAbs

Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis

(2014) Diana Hernández-Flórez et al.   RHEUMATOLOGY INTERNATIONAL

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease

(2013) R. Khanna et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels

(2013) Begoña Ruiz-Argüello et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease

(2013) Stephane Paul et al.   INFLAMMATORY BOWEL DISEASES

Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohnʼs Disease

(2013) Casper Steenholdt et al.   THERAPEUTIC DRUG MONITORING

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

(2010) S. Ben-Horin et al.   GUT

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

(2010) Casper Steenholdt et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

(2008) F Schnitzler et al.   GUT